Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.

被引：0
|
作者：
Ghoshal, Pushpankur [1 ]
Chitta, Kasyapa [1 ]
Vujcic, Slavoljub [1 ]
Gaddy, Jacquelyne [1 ]
Miles, Kiersten M. [1 ]
Stein, Leighton [1 ]
Sher, Taimur [1 ]
Lee, Kelvin P. [1 ]
Chanan-Khan, Asher A. [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1106 / 1107
页数：2
相关论文
共 50 条
  • [1] Agonistic antibody to TRAIL-R1 (Mapatumumab) and low dose Bortezomib induce apoptosis in multiple myeloma while preserving dendritic cell function
    Neeson, Paul
    Chen, Karen
    Tai, Tsin
    Shin, Amanda
    Tainton, Kellie
    Fielding, Kate
    Davis, Joanne
    Prince, H.
    Humphreys, Robin
    Ritchie, David
    CANCER RESEARCH, 2009, 69
  • [2] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy
    Carrell, Jeffrey
    Humphreys, Robin
    CANCER RESEARCH, 2009, 69
  • [3] Bortezomib Reverts Stroma-Mediated Resistant to APO2L/TRAIL in Multiple Myeloma.
    Parquet, Nancy
    Mead, Mark
    Anasetti, Claudio
    Dalton, William S.
    Perez, Lia
    BLOOD, 2009, 114 (22) : 1097 - 1097
  • [4] Synergism of gambogenic acid with bortezomib induce apoptosis of multiple myeloma.
    Chen, Runzhe
    Zhang, Hongming
    Liu, Ping
    Wu, Xue
    Chen, Baoan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy A.
    Carrel, Jeffrey A.
    McCormick, Kathy
    Sun, David
    Humphreys, Robin
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) : 292 - 302
  • [6] Bortezomib Targets Stroma-Mediated APO2L/TRAIL Apoptosis Resistance in Multiple Myeloma.
    Perez, Lia
    Parquet, Nancy
    Anasetti, Claudio
    Dalton, William
    BLOOD, 2008, 112 (11) : 588 - 588
  • [7] Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1
    Moretto, Patricia
    Hotte, Sebastien J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (03) : 311 - 325
  • [8] Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in multiple myeloma.
    Fandy, T
    Shankar, S
    Luetrakul, T
    Srivastava, R
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6164S - 6164S
  • [9] cAMP induces cell apoptosis in multiple myeloma and overcomes bortezomib resistance
    Wang, Yingying
    Tang, Yong
    Hang, Haifang
    Wang, Mingming
    Pang, Yuyang
    Yu, Yehua
    Wu, Yingli
    Zhu, Qi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (01): : 16 - +
  • [10] Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis
    Balsas, Patricia
    Lopez-Royuela, Nuria
    Galan-Malo, Patricia
    Anel, Alberto
    Marzo, Isabel
    Naval, Javier
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (05) : 804 - 812
12345